FMP
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
3.9 CAD
-0.03 (-0.769%)
About
ceo
Dr. James A. Helliwell FRCPC, M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.eupraxiapharma.com
exchange
TSX
Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as ...
CIK
N/A
ISIN
CA29842P1053
CUSIP
N/A
Address
2067 Cadboro Bay Road
Phone
250-590-3968
Country
CA
Employee
29
IPO Date
Mar 9, 2021
Summary
CIK
-
Exchange
TSX
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
CA29842P1053
Country
CA
Price
3.9
Beta
1.13
Volume Avg.
69.03k
Market Cap
138.93M
Shares
-
52-Week
3.44-9.1
DCF
0.49
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.33
P/B
-
Website
https://www.eupraxiapharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EPRX.TO News
It looks like there's no news available.
